Oil prices hold sharp losses with focus on secondary India tariffs
Investing.com -- Shares of Repligen (NASDAQ: NASDAQ:RGEN) climbed 9% following the release of its fourth-quarter earnings and future financial guidance that exceeded analysts’ expectations. The life sciences company, known for its bioprocessing technology, reported a fourth-quarter earnings per share (EPS) of $0.44, which was $0.03 higher than the consensus estimate of $0.41. Revenue for the quarter was reported at $168 million, marginally surpassing the consensus estimate of $167.67 million.
The company has also provided an optimistic forecast for fiscal year 2025, expecting EPS to be between $1.67 and $1.76, compared to the consensus estimate of $1.71. Revenue projections for the same period are set at $685-710 million, against the consensus forecast of $692.8 million.
Repligen’s performance in the fourth quarter saw a 13% increase in revenue excluding COVID-related revenue, despite a two-point currency headwind. Orders surpassed revenue by 6%, driven by growth in the Filtration and Analytics franchises. The company also reported a significant sequential increase in revenues from CDMOs and capital equipment, which rose approximately 20% and 30%, respectively.
President and CEO Olivier Loeillot expressed confidence in achieving the company’s 2025 guidance, citing strong order momentum in the second half of the year. Repligen’s recent acquisition of Tantti Laboratory Inc. and the launch of innovative products like the AVIPure® dsRNA resin are expected to contribute to future growth.
Jefferies analyst Matthew Stanton provided a positive outlook, stating, "With stock off ~15% since the Sartorius print a few weeks ago, a solid 4Q showing, ’25 guide slightly ahead and largely upbeat order commentary was plenty for shares to move higher." Stanton’s comment reflects the market’s reaction to Repligen’s solid financial performance and the company’s potential for growth in the coming year.
Investors seem to be responding favorably to Repligen’s recent achievements and future prospects, as reflected in the stock’s upward movement. The company’s focus on expanding its product offerings and commitment to sustainability, highlighted in its 2023 Sustainability report, also play a role in shaping its positive market image. As Repligen continues to navigate the bioprocessing market, its strategic initiatives and financial guidance set a promising course for 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.